Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers

Figure 4 Schematic of Bromodomain and extra-terminal inhibitors combined with anti-programmed death-1-ligand-1 Ab therapeutic effects. Bromodomain and extra-terminal (BET) inhibitors treatment impacts programmed death-1-ligand-1 (PD-L1) expression, resulting in sensitizing the liver response to anti-PD-L1 blockade. Also, the co-inhibition can inhibit liver-infiltrating monocytic myeloid-derived suppressor cells and enhance tumor-infiltrating CD8+ T cells, which contributes to the elimination of drug resistance. BET: Bromodomain and extra-terminal; HCC: Hepatocellular carcinoma; M-MDSCs: Monocytic myeloid-derived suppressor cells; PD-L1: Programmed death-1-ligand-1.